NEW YORK (GenomeWeb News) – Nanosphere announced after the close of the market on Tuesday an agreement to sell up to $30 million of shares of its common stock to investment fund Aspire Capital.

Aspire is an existing investor in Nanosphere and invested in the firm's public offering in September that raised $27.7 million. In a document filed with the US Securities and Exchange Commission on Tuesday, Nanosphere said that the agreement with Aspire has a term of 24 months.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.